Market Place
Sourcing Support
Merus to Present at Upcoming Investor Conferences
06 Nov 2024 //
GLOBENEWSWIRE
Merus Receives FDA extension of PDUFA for zenocutuzumab
05 Nov 2024 //
GLOBENEWSWIRE
Merus Reports Q3 2024 Financial Results & Business Update
31 Oct 2024 //
GLOBENEWSWIRE
Merus Doses First Patient In Ph 3 Trial Of Petosemtamab
30 Sep 2024 //
GLOBENEWSWIRE
Merus Announces Abstract Accepted for ESMO Asia Congress 2024
17 Sep 2024 //
GLOBENEWSWIRE
Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
06 Aug 2024 //
GLOBENEWSWIRE
Merus Reports Q2 2024 Results And Provides Business Update
01 Aug 2024 //
GLOBENEWSWIRE
Merus Doses First Patient In Phase 3 Petosemtamab Trial For HNSCC
24 Jul 2024 //
GLOBENEWSWIRE
Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
08 Jul 2024 //
GLOBENEWSWIRE
Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
01 Jul 2024 //
GLOBENEWSWIRE
Merus` MCLA-129 Shows Efficiency In METex14 NSCLC At ASCO 2024
03 Jun 2024 //
GLOBENEWSWIRE
Merus` MCLA-145 Mono/Combo Data In Solid Tumors At ASCO 2024
02 Jun 2024 //
GLOBENEWSWIRE
Merus To Participate In Fireside Chat At Jefferies Healthcare
29 May 2024 //
GLOBENEWSWIRE
Merus Announces Pricing of Upsized Public Offering of Common Shares
29 May 2024 //
GLOBENEWSWIRE
Merus: Petosemtamab Combo Robust Response, Safety In Head/Neck Cancer
28 May 2024 //
GLOBENEWSWIRE
Merus N.V. Announces Proposed Public Offering of Common Shares
28 May 2024 //
GLOBENEWSWIRE
Merus Petosemtamab Hnscc Abstract: 1L With Pembro At 2024 Asco
23 May 2024 //
GLOBENEWSWIRE
Merus Abstracts Published: For 2024 Asco Annual Meeting
23 May 2024 //
GLOBENEWSWIRE
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
13 May 2024 //
GLOBENEWSWIRE
Merus Q1 2024 Financials, Business Update
08 May 2024 //
GLOBENEWSWIRE
Merus` Zeno BLA For NRG1+ NSCLC, PDAC Accepted For Priority Review
06 May 2024 //
GLOBENEWSWIRE
Merus Abstracts Accepted for ASCO 2024 Presentation
24 Apr 2024 //
GLOBENEWSWIRE
Merus Presents Preclinical Data at the AACR
08 Apr 2024 //
GLOBENEWSWIRE
Merus to Participate in a Fireside Chat at the 23rd Needham Virtual Conference
03 Apr 2024 //
GLOBENEWSWIRE
Gilead bets $1.5B-plus on Merus` trispecifc T-cell engagers
06 Mar 2024 //
FIERCE BIOTECH
Merus Announces Publication of an Abstract for Presentation
05 Mar 2024 //
GLOBENEWSWIRE
Merus to Participate in Fireside Chat at the Leerink Partners Global Conference
04 Mar 2024 //
PRESS RELEASE
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023
28 Feb 2024 //
GLOBENEWSWIRE
Merus shares dip as lung cancer data reveal 3 patient deaths
05 Dec 2023 //
FIERCE BIOTECH
Merus Announces Publication of Abstracts on MCLA-129 for Presentation
26 Nov 2023 //
GLOBENEWSWIRE
Merus Announces Financial Results for the Third Quarter 2023
02 Nov 2023 //
GLOBENEWSWIRE
Merus to Participate in Upcoming Investor Conferences
01 Nov 2023 //
GLOBENEWSWIRE
Merus™ Zeno Data Continues to Demonstrate Durable Responses in NRG1+ Cancer
23 Oct 2023 //
GLOBENEWSWIRE
Merus` NRG1+ drug responses edge up in tough pancreatic cancer
23 Oct 2023 //
FIERCE BIOTECH
Merus Announces Business Update Conference Call
15 Oct 2023 //
GLOBENEWSWIRE
Merus Announces Abstracts Accepted for Presentation at ESMO Asia Congress 2023
06 Oct 2023 //
GLOBENEWSWIRE
Merus to Participate in Upcoming Investor Conferences
31 Aug 2023 //
GLOBENEWSWIRE
Merus N.V. Announces Proposed Public Offering of Common Shares
09 Aug 2023 //
GLOBENEWSWIRE
Merus Announces Pricing of Public Offering of Common Shares
09 Aug 2023 //
GLOBENEWSWIRE
Merus Announces Financial Results for the Second Quarter 2023
07 Aug 2023 //
GLOBENEWSWIRE
Merus Announces Two Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion NSCLC
28 Jul 2023 //
GLOBENEWSWIRE
FDA Grants Breakthrough Therapy Designation to Zenocutuzumab for NRG1+ PC
30 Jun 2023 //
ONCLIVE
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the USFDA
29 Jun 2023 //
GLOBENEWSWIRE
Merus Appoints Life Sciences Strategic & Financial Veteran Greg Perry as CFO
15 Jun 2023 //
GLOBENEWSWIRE
Merus to Participate in a Fireside Chat at Jefferies Healthcare Conference 2023
31 May 2023 //
GLOBENEWSWIRE
Merus Announces Financial Results for the 1Q 2023 and Provides Business Update
04 May 2023 //
GLOBENEWSWIRE
Merusâ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity
17 Apr 2023 //
GLOBENEWSWIRE
Merus Announces Publication of an Abstract on Petosemtamab at the AACR
14 Apr 2023 //
GLOBENEWSWIRE
Merus Announces Financial Results for Q4 and Full Year 2022
28 Feb 2023 //
GLOBENEWSWIRE
Merus to Participate in Upcoming Investor Conferences
01 Feb 2023 //
GLOBENEWSWIRE
CORRECTING and REPLACING --Merus Provides 2023 Outlook
09 Jan 2023 //
GLOBENEWSWIRE
Merus Provides 2023 Outlook
08 Jan 2023 //
GLOBENEWSWIRE
Merus Announces Financial Results for the Third Quarter
03 Nov 2022 //
GLOBENEWSWIRE
Merus Presents First in Human Data on MCLA-129 at ENA Symposium
26 Oct 2022 //
GLOBENEWSWIRE
Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC
12 Oct 2022 //
GLOBENEWSWIRE
Merus Announces Poster Presentation on MCLA-129 at the 34th EORTC/NCI/AACR
07 Sep 2022 //
GLOBENEWSWIRE
Merus to Participate in a Panel Discussion at Citi`s 17th Annual BioPharma
01 Sep 2022 //
GLOBENEWSWIRE
Merus Announces Financial Results for the Second Quarter
08 Aug 2022 //
GLOBENEWSWIRE
Merus looks to beat Elevation to NRG1+ summit as BLA filing approaches
06 Jun 2022 //
ENDPTS
